Last reviewed · How we verify
Lunesta
At a glance
| Generic name | Lunesta |
|---|---|
| Also known as | eszopiclone |
| Sponsor | Walter Reed Army Medical Center |
| Target | Gamma-aminobutyric acid receptor subunit alpha-1, Gamma-aminobutyric acid receptor subunit alpha-2, Gamma-aminobutyric acid receptor subunit alpha-3 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Insomnia
Common side effects
- Unpleasant taste
- Headache
- Somnolence
- Respiratory infection
- Dizziness
- Dry mouth
- Rash
- Anxiety
- Hallucinations
- Viral infections
Key clinical trials
- National Adaptive Trial for PTSD Related Insomnia (PHASE3)
- Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea (PHASE3)
- Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP) (PHASE2)
- Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD (PHASE4)
- Endotypic Traits and Obstructive Sleep Apnea Surgery (PHASE2)
- Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN) (PHASE4)
- Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial (NA)
- The Study in Outpatient Medicine Using Nudges to Improve Sleep (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lunesta CI brief — competitive landscape report
- Lunesta updates RSS · CI watch RSS
- Walter Reed Army Medical Center portfolio CI